BIOTECH BY THE LAKE 2022
INVESTOR SUMMIT
Biotech by the Lake 2022 Investor Summit
Tuesday, June 28, 2022
9:00 AM – 12:30 PM Central Time
(7:00 AM – 10:30 AM Pacific Time; 8:00 AM – 11:30 AM Mountain Time; 10:00 AM – 1:30 PM Eastern Time)
The market for protein therapeutics is expected to grow by more than $115 billion between 2020 and 2025, according to industry experts, spurred by advances in proteomics technologies and the Human Proteoform Project, an ambitious, $1.3 billion initiative to map every protein in the human body.
The fourth annual Biotech by the Lake Investor Summit, hosted by Chemistry of Life Processes Institute at Northwestern and Oppenheimer, will provide an exclusive look at next-generation protein therapeutics developed by Northwestern’s top translational scientists. The program will also feature biotech and pharma industry leaders who will discuss the hottest trends and grand challenges in protein therapeutics. Experts will also weigh in on biotech investing and financing in challenging dynamics as well as opportunities within Chicago’s bustling biotech community and beyond.
PROGRAM
NORTHWESTERN FACULTY PRESENTERS
9:00 a.m. (CST) - Welcome and Introduction
Neil L. Kelleher, PhD
Walter and Mary E. Glass Professor of Molecular Biosciences; Professor of Chemistry, Northwestern; Professor of Medicine (Hematology & Oncology), Feinberg School of Medicine; Director, Chemistry of Life Processes Institute; Director, Northwestern Proteomics; Northwestern University
9:10 a.m. (CST) - Rare Cell Profiling for Therapeutic Discovery and Development
Shana Kelley, PhD
Neena B. Schwartz Professor of Chemistry and Biomedical Engineering, Northwestern University; Member, Chemistry of Life Processes Institute, Northwestern University
9:35 a.m. (CST) - Using Genetic Signals to Develop New Protein Biologics for Muscle Disease
Elizabeth McNally MD, PhD, PhD
Elizabeth Ward Professor and Director Center for Genetic Medicine, Northwestern University Feinberg School of Medicine
10:00 a.m. (CST) - Small-Molecule Kalirin Antagonists for the Treatment of Chronic Neuropathic Pain and Other Conditions
Peter Penzes, PhD
Director, Center for Autism and Neurodevelopment; Ruth and Evelyn Dunbar Professor of Psychiatry and Behavioral Sciences; Professor of Neuroscience, Pharmacology and Psychiatry and Behavioral Sciences, Northwestern University Feinberg School of Medicine
10:25 a.m. (CST) - Supramolecular Peptide Medicines
Samuel I. Stupp, PhD
Board of Trustees Professor of Materials Science, Chemistry, Medicine, and Biomedical Engineering; Director, Simpson Querrey Institute, Northwestern University
PANEL DISCUSSION: HOT TOPICS IN PROTEIN THERAPEUTICS AND TECHNOLOGIES
10:50 a.m. (CST)
(Please check back later for more information about panelists.)
Moderator:
Karen Tkach Tuzman, PhD
Senior Editor, Head of Discovery and Preclinical Development
BioCentury Inc.
Panelist:
Ginger S. Johnson, PhD
President, Commercial BioConsulting
Lumanity
Panelist:
Parag Mallick, PhD
Associate Professor of Radiology, Stanford University
Founder and Chief Scientist
Nautilus Biotechnology
Panelist:
Vini Mani, PhD
Head of Platform
ProFound Therapeutics
CORPORATE PRESENTERS:
11:15 a.m. (CST) - 'Next-generation Antibody Therapeutics'
Arvind Rajpal, PhD
Vice President Large Molecule Drug Discovery – Antibody Engineering & Protein Chemistry
Genentech
11:40 (CST) - ‘Solving the Grand Challenges of Protein Therapeutics’
Alan J. Russell, PhD
Vice President of Research, Biologic Therapeutic Discovery
Amgen Inc.
PANEL DISCUSSION: BIOTECH FINANCING AND INVESTING IN CHALLENGING DYNAMICS
12:05 p.m.
(Please check back soon for more information about panelists.)
Moderator:
Jay Olson, CFA
Research Analyst
Oppenheimer & Co.
Panelist:
Margarita Chavez, JD
Managing Director
AbbVie Ventures
Panelist:
Stefan Loren, PhD
Managing Director, Life Sciences
Oppenheimer & Co.
Panelist:
Scott Morenstein
Managing Director
BAAM – New York
Blackstone
Panelist:
William Slattery
Partner
Deerfield
Acknowledgment
We would like to express our gratitute to the members of the Chemistry of Life Processes Institute’s Executive Advisory Board (EAB) for their enthusiastic support for the Biotech by the Lake Investor Summit series. Our special thanks to EAB member Sujal Shah, President and CEO of CymaBay Therapeutics (CBAY), whose vision, guidance and leadership made this investor series possible.
